# US 11,433,085 B2 · Phospholipid compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,085 B2
- Document ID: US11433085B2
- Status: Granted
- Kind: B2
- Application number: 16/653,591
- Filed: 2019-10-15
- Published: 2020-02-13
- Granted: 2022-09-06
- Earliest claimed: 2016-06-29
- Assignees: Machavert Pharmaceuticals LLC
- Applicants: Machavert Pharmaceuticals LLC
- Inventors: Jakub Staszak-Jirkovsky; Lukas Kobr; Gregory Miknis; Colleen Hudson; Luca Monfregola; Pavel Jirkovsky; Zbon{hacek over (c)}áková Milada; Jason Duex; Pitchaimani Kandasamy
- Web page: https://patentgrep.com/patent/US11433085B2

## CPC

- A61K 31/688: both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 35/57: Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 2236/00: Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions involving a modified egg yolk extract for use as an effective anti-cancer agent are described. The modified egg yolk extract involves specific fractions of phosphatidylcholines and sphingomyelins modified and produced from a chemical synthesis applied to the extract that produce a beneficial effect on the inhibition of cancerous cell growth. Methods of administering these compositions are also described.

## Claims

### Claim 1

A method of treating lung cancer in a human patient in need thereof comprising administering to said patient a pharmaceutical composition consisting of a plurality of phosphatidylcholine compounds and one or more pharmaceutically acceptable diluents, excipients, and/or carriers:
wherein said plurality of phosphatidylcholine compounds comprise 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine and one or more phosphatidylcholines selected from the group consisting of:
1-palmitoleoyl-2-linoleoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-α-linolenoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine,
1,2-dilinoleoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine,
1-α-linolenoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine,
1-palmitoleoyl-2-oleoyl-sn-glycero-3-phosphocholine,
1-palmitoleoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-osbodnoyl-sn-glycero-3-phosphocholine,
1-oleoyl-2-arachidonoyl-sn-glycero-3-phosphocholine,
1-oleoyl-2-linoleoyl-sn-glycero-3-phosphocholine,
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine,
1-oleoyl-2-docosahexenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphocholine,
1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine, and
1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine.